Oxurion NV issued a business and a financial update for the 3 months ending March 31, 2019. Oxurion is developing a competitive pipeline of disease modifying drug candidates for diabetic eye disease, particularly DME.
The Oxurion clinical development pipeline consists of novel products with different modes of action, which, together potentially give the company access to a significant share of the diabetic eye disease market. Oxurion’s clinical pipeline comprises of:
- A human placental growth factor (PlGF) neutralizing an onoclonal antibody (THR-317) which is in a phase 2 study evaluating the efficacy and safety of intravitreal THR-317 when administered in combination with ranibizumab (Lucentis), for the treatment of DME. Recruitment of this study is completed, and results are expected in early Q3 2019.
In addition, THR-317 is being evaluated in a phase 2 study for the treatment of Idiopathic Macular Telangiectasia Type 1 (MacTel 1), a rare disease that affects the macula and can lead to vision loss. First data from this study are expected towards the end of 2019.
- A potent plasma kallikrein inhibitor (THR-149) is in a phase 1 multicenter, dose escalation study for the treatment of DME. Recruitment of this study has recently completed with results anticipated by early Q3 2019.
- A small molecule pan-RGD integrin antagonist (THR-687) being developed to treat a broad range of patients with diabetic eye disease. THR-687 entered the clinic in September 2018. Results from the on-going Phase 1 study are expected towards the end of 2019.
“We are making excellent progress with our competitive pipeline of disease-modifying drug candidates for diabetic eye disease, the leading cause of blindness in people of working age,” Patrik De Haes, MD, CEO of Oxurion, said in a company news release. “We have completed recruitment ahead of schedule of our Phase 2 study evaluating the efficacy and safety of intravitreal THR-317 when administered in combination with ranibizumab (Lucentis), for the treatment of DME. We have also completed recruitment of our phase 1 study with THR-149. Results from these studies are expected by Q3 2019. Later in the year we plan to announce the results from a phase 1 study with THR-687 and a phase 2 study with THR-317 in patients with MacTel1. We are confident that 2019 will be a milestone year for Oxurion as we continue to advance our clinical pipeline of novel disease-modifying therapies and remain confident in their potential to preserve the vision of patients with diabetic eye disease.”
Oxurion Clinical and Preclinical Development Update
THR-317 – a Humanized mAb Against Human PlGF for the treatment of DME
THR-317 (anti-PlGF) is a recombinant humanized monoclonal antibody directed against the receptor-binding site of human placental growth factor (PlGF) being developed for the treatment of DME. In pre-clinical models, anti-PlGF has been shown, in addition to anti-angiogenic and anti-edema properties, to be anti-inflammatory.
Phase 2 Clinical study evaluating THR-317 in combination with ranibizumab (Lucentis), an anti-VEGF
In April 2019, enrollment was completed, ahead of schedule, for the phase 2 study evaluating the efficacy and safety of intravitreal THR-317 administered in combination with ranibizumab (Lucentis) a VEGF inhibitor, for the treatment of DME.
Initial results from this phase 2 clinical study are anticipated in early Q3 2019. Results from this trial will provide the clinical data needed to plan the next stages of THR-317’s clinical development.
Simultaneously inhibiting VEGF (ranibizumab) and PlGF (THR-317) could deliver better efficacy than either treatment alone. Nonclinical experiments indicate that anti-PlGF in the presence of an anti-VEGF antibody has an additive effect inhibiting the growth of new blood vessels (Van de Veire et al.,2010), a disease hallmark of DR.
Phase 2 clinical study evaluating THR-317 for treatment of MacTel1
In September 2018, Oxurion started a phase 2 multicenter study evaluating the efficacy and safety of intravitreal THR-317 for the treatment of Macular Telangiectasia Type 1 (MacTel 1). MacTel 1 is a rare disease that affects the macula and can lead to vision loss. There is currently no effective treatment for MacTel 1.
This phase 2 study plans to enroll 10 patients with macular edema caused by MacTel 1, who will each receive three 8mg intravitreal THR-317 injections over a period of 2 months. Efficacy and safety of the therapy will be assessed via functional and anatomic endpoints.
Initial results from this clinical study are anticipated towards the end of 2019.
THR-149 – a plasma kallikrein inhibitor for treatment of DME
Phase 1 study evaluating THR-149, a Potent Plasma Kallikrein inhibitor, for the treatment of DME
THR-149 is a novel plasma kallikrein inhibitor, generated by using Bicycle Therapeutics’ Bicycles technology platform, that is being developed for the treatment of DME.
THR-149 acts through inhibition of the Plasma Kallikrein-Kinin (PKaI-Kinin) system, which is considered a validated target for DME.
Preclinical studies involving THR-149 were published in The Journal of Medicinal Chemistry in March 2018 and presented by Oxurion’s senior scientist Dr Tine Van Bergen at the Annual Meeting of the European Association for the Study of Diabetes Eye Complications Study Group (EASDec). The data demonstrate the potency and efficacy of bicyclic peptide inhibitors of PKal, such as THR-149, via a VEGF-independent pathway.
In May 2018, Oxurion initiated a Phase 1 clinical study evaluating the safety of a single intravitreal injection of escalating dose levels of THR-149 in patients with DME.
Oxurion announced in April 2019 that all patients had been enrolled in the clinical study, with initial results anticipated by early Q3.
THR-687 – an integrin antagonist for treatment of DME
Phase 1 study evaluating THR-687, a novel pan-RGD integrin antagonist for the treatment of DME
Oxurion is developing THR-687, a novel pan-RGD integrin antagonist, to preserve vision of a broad range of patients with diabetic eye disease. This wide-ranging potential is based on the hypothesis that integrin inhibition can address many of the processes that result in the pathological angiogenesis and vascular leakage that cause diabetic eye disease.
Oxurion is initially targeting THR-687 for DME. In September 2018, THR-687 initiated a phase 1 multicenter, dose escalation study evaluating the safety of a single intravitreal injection of THR-687 for the treatment of patients with DME. A maximum of 15 patients will be enrolled, with initial results anticipated by the end of 2019.
Oxurion had €76.2 million in cash and investments at the end of March 2019. This compares with €85.1 million as of the end of December 2018.